

## Position on Water

When a business grows, it is generally associated with increased water consumption, chemical residues in waste water and medicinal products disposed of by patients. This may potentially cause environmental changes and affect aquatic ecosystems. Therefore, Lundbeck considers water usage and wastewater emissions as two of our significant environmental aspects.

In many areas of the world, the scarcity of clean water presents significant challenges to public health and the environment. Approximately 60% of Lundbeck's water usage for production and research activities takes place in areas classified as low-medium-risk areas ([World Resource Institute](#)). The remaining 40% are placed in low-risk areas. Only a negligible part of Lundbeck's global operations, including suppliers, takes place in classified medium-high-risk areas.

Nevertheless, Lundbeck wants to act responsibly and ensure that our water usage and waste water emission does not negatively affect communities by diminishing the supply of clean water and degrading the water quality. Therefore, all research and production facilities at Lundbeck are required to quantify water consumption, minimize water usage when possible, and control the wastewater.

Chemical residues may cause a potential risk to the aquatic ecosystem, and we acknowledge the potential environmental risk posed by medicinal residues from patients. Lundbeck takes the matter seriously and monitor the environmental effects of the active pharmaceutical ingredients in our new medicinal products. Through biological and physical/chemical studies, we assess the effect on biodiversity to various aquatic organisms and ecosystems as an integral part of our Environmental Risk Assessment process. The knowledge gained is applied to the design and manufacturing process, resulting in the least possible environmental impact. We believe that the work to improve our understanding of the fate and effect of pharmaceuticals in the environment may help to protect ecosystems. Through our membership of EFPIA we support the Eco-Pharmaco-Stewardship initiative that considers the entire life-cycle of pharmaceuticals.

Our future key challenges and opportunities with regard to water include:

- Improving our knowledge about active pharmaceutical ingredients in our wastewater when introducing new pharmaceuticals.
- Improving our mapping and analysing the differences in water consumption at our sites for production, research and development in order to identify possibilities for reducing our water consumption.
- Understanding water-related risks and opportunities in our operations.
- Supporting initiatives to improve data quality and minimising the presence and effects of pharmaceuticals in the environment. E.g. by participating in European and national industry networks to share experience.
- Developing and maintaining our environmental principles concerning water use and wastewater in supplier audits.
- Keeping an open and honest dialogue with our stakeholders e.g. by reporting our HSE performance to UN Global Compact and FTSE4GOOD.

In our UN Global Compact Progress report on [www.Lundbeck.com](http://www.Lundbeck.com) you can read more about our activities and performance.